Technical Analysis for LABP - Landos Biopharma, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
A | 6.64 | 0.00% | 0.00 |
LABP closed unchanged on Monday, March 18, 2024, on approximately normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
Earnings due: Mar 21
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Support | Bullish | 0.00% | |
Doji - Bearish? | Reversal | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
New 52 Week Closing High | Bullish | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Stochastic Reached Overbought | Strength | 2.47% | |
Inside Day | Range Contraction | 2.47% | |
Overbought Stochastic | Strength | 2.47% | |
Gapped Down | Weakness | 2.47% | |
Gapped Down | Weakness | 2.47% |
Alert | Time |
---|---|
20 DMA Support | about 19 hours ago |
60 Minute Opening Range Breakdown | about 19 hours ago |
Fell Below 20 DMA | about 19 hours ago |
Fell Below 10 DMA | about 19 hours ago |
10 DMA Support | about 21 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/21/2024
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. The company was founded in 2017 and is headquartered in Blacksburg, Virginia.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Autoimmune Disease Rheumatoid Arthritis Inflammatory Bowel Disease Gastroenterology Ulcerative Colitis Abdominal Pain Colitis Crohn's Disease Diarrhea Diabetic Nephropathy
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Autoimmune Disease Rheumatoid Arthritis Inflammatory Bowel Disease Gastroenterology Ulcerative Colitis Abdominal Pain Colitis Crohn's Disease Diarrhea Diabetic Nephropathy
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 6.73 |
52 Week Low | 2.328 |
Average Volume | 10,942 |
200-Day Moving Average | 4.29 |
50-Day Moving Average | 5.48 |
20-Day Moving Average | 6.34 |
10-Day Moving Average | 6.49 |
Average True Range | 0.41 |
RSI (14) | 68.85 |
ADX | 15.62 |
+DI | 15.36 |
-DI | 13.99 |
Chandelier Exit (Long, 3 ATRs) | 5.50 |
Chandelier Exit (Short, 3 ATRs) | 6.48 |
Upper Bollinger Bands | 6.88 |
Lower Bollinger Band | 5.80 |
Percent B (%b) | 0.78 |
BandWidth | 17.06 |
MACD Line | 0.32 |
MACD Signal Line | 0.35 |
MACD Histogram | -0.0292 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 7.20 | ||||
Resistance 3 (R3) | 7.15 | 6.91 | 7.10 | ||
Resistance 2 (R2) | 6.91 | 6.77 | 6.94 | 7.07 | |
Resistance 1 (R1) | 6.78 | 6.68 | 6.66 | 6.83 | 7.04 |
Pivot Point | 6.54 | 6.54 | 6.49 | 6.57 | 6.54 |
Support 1 (S1) | 6.41 | 6.40 | 6.29 | 6.46 | 6.24 |
Support 2 (S2) | 6.17 | 6.31 | 6.20 | 6.21 | |
Support 3 (S3) | 6.04 | 6.17 | 6.18 | ||
Support 4 (S4) | 6.09 |